Hua Susan, Marks Ellen, Schneider Jennifer J, Keely Simon
The School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.
The School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia; Gastrointestinal Research Group, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
Nanomedicine. 2015 Jul;11(5):1117-32. doi: 10.1016/j.nano.2015.02.018. Epub 2015 Mar 14.
Colon targeted drug delivery is an active area of research for local diseases affecting the colon, as it improves the efficacy of therapeutics and enables localized treatment, which reduces systemic toxicity. Targeted delivery of therapeutics to the colon is particularly advantageous for the treatment of inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease. Advances in oral drug delivery design have significantly improved the bioavailability of drugs to the colon; however in order for a drug to have therapeutic efficacy during disease, considerations must be made for the altered physiology of the gastrointestinal (GI) tract that is associated with GI inflammation. Nanotechnology has been used in oral dosage formulation design as strategies to further enhance uptake into diseased tissue within the colon. This review will describe some of the physiological challenges faced by orally administered delivery systems in IBD, the important developments in orally administered nano-delivery systems for colon targeting, and the future advances of this research.
Inflammatory Bowel Disease (IBD) poses a significant problem for a large number of patients worldwide. Current medical therapy mostly aims at suppressing the active inflammatory episodes. In this review article, the authors described and discussed the various approaches current nano-delivery systems can offer in overcoming the limitations of conventional drug formulations.
结肠靶向给药是针对影响结肠的局部疾病的一个活跃研究领域，因为它提高了治疗效果并实现了局部治疗，从而降低了全身毒性。将治疗药物靶向递送至结肠对于治疗炎症性肠病（IBD）特别有利，炎症性肠病包括溃疡性结肠炎和克罗恩病。口服给药设计的进展显著提高了药物在结肠的生物利用度；然而，为了使药物在疾病期间具有治疗效果，必须考虑与胃肠道（GI）炎症相关的胃肠道生理变化。纳米技术已被用于口服剂型设计，作为进一步增强药物在结肠内病变组织摄取的策略。本综述将描述口服给药系统在IBD中面临的一些生理挑战、用于结肠靶向的口服纳米给药系统的重要进展以及该研究的未来进展。
炎症性肠病（IBD）给全球大量患者带来了重大问题。当前的药物治疗主要旨在抑制活动性炎症发作。在这篇综述文章中，作者描述并讨论了当前纳米给药系统在克服传统药物制剂局限性方面可以提供的各种方法。
